Payment overview · 2025
General Payments
$162.22
2 reported records · 2 companies
Healthcare provider profile · identity verified
Surendra Patel, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · WAUKESHA, WI · NPI 1265748404
Verified facts
What the public records show
CMS Open Payments records show Surendra Patel, M.D. received $162.22 in general payments during 2025 across 2 reported records.
Otsuka America Pharmaceutical, Inc. accounted for 77.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 2 associated products.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $124.99 | 77.0% | 1 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $37.23 | 22.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $162.22 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $124.99 | 1 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $37.23 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
No publishable same-company prescribing overlap was found in the loaded Part D year. This does not mean the doctor never prescribed a drug reported elsewhere by a paying company.
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Eliquis | Apixaban | 376 | 54 |
| Atorvastatin Calcium | Atorvastatin Calcium | 370 | 83 |
| Furosemide | Furosemide | 334 | 57 |
| Levothyroxine Sodium | Levothyroxine Sodium | 313 | 55 |
| Pantoprazole Sodium | Pantoprazole Sodium | 283 | 66 |
| Gabapentin | Gabapentin | 272 | 69 |
| Sertraline Hcl | Sertraline Hcl | 216 | 43 |
| Amlodipine Besylate | Amlodipine Besylate | 186 | 43 |
| Metoprolol Tartrate | Metoprolol Tartrate | 178 | 43 |
| Tamsulosin Hcl | Tamsulosin Hcl | 175 | 37 |
| Losartan Potassium | Losartan Potassium | 151 | 35 |
| Potassium Chloride | Potassium Chloride | 150 | 29 |
| Metoprolol Succinate | Metoprolol Succinate | 134 | 41 |
| Metformin Hcl | Metformin Hcl | 131 | 25 |
| Omeprazole | Omeprazole | 131 | 30 |
| Clopidogrel | Clopidogrel Bisulfate | 128 | 29 |
| Carvedilol | Carvedilol | 122 | 25 |
| Lisinopril | Lisinopril | 122 | 28 |
| Hydralazine Hcl | Hydralazine Hcl | 105 | 20 |
| Duloxetine Hcl | Duloxetine Hcl | 104 | 16 |
| Trazodone Hcl | Trazodone Hcl | 101 | 22 |
| Baclofen | Baclofen | 100 | 19 |
| Divalproex Sodium | Divalproex Sodium | 97 | 22 |
| Quetiapine Fumarate | Quetiapine Fumarate | 85 | 22 |
| Mirtazapine | Mirtazapine | 82 | 24 |
| Warfarin Sodium | Warfarin Sodium | 79 | 12 |
| Jardiance | Empagliflozin | 75 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 75 | 19 |
| Escitalopram Oxalate | Escitalopram Oxalate | 74 | 16 |
| Bumetanide | Bumetanide | 73 | 17 |
| Famotidine | Famotidine | 68 | 13 |
| Levetiracetam | Levetiracetam | 67 | 20 |
| Bupropion Xl | Bupropion Hcl | 59 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 58 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 55 | 13 |
| Paroxetine Hcl | Paroxetine Hcl | 53 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 52 | 19 |
| Risperidone | Risperidone | 52 | suppressed |
| Sucralfate | Sucralfate | 51 | suppressed |
| Olanzapine | Olanzapine | 49 | suppressed |
| Simvastatin | Simvastatin | 47 | 12 |
| Memantine Hcl | Memantine Hcl | 45 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 45 | 31 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 45 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 45 | 16 |
| Cholestyramine | Cholestyramine (With Sugar) | 44 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 44 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 43 | 15 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 43 | 14 |
| Pravastatin Sodium | Pravastatin Sodium | 43 | 15 |
| Lamotrigine | Lamotrigine | 42 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 42 | 13 |
| Doxazosin Mesylate | Doxazosin Mesylate | 41 | suppressed |
| Prednisone | Prednisone | 41 | 22 |
| Allopurinol | Allopurinol | 40 | 12 |
| Glipizide | Glipizide | 40 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 39 | suppressed |
| Finasteride | Finasteride | 39 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 39 | 22 |
| Alendronate Sodium | Alendronate Sodium | 38 | 11 |
| Ezetimibe | Ezetimibe | 37 | suppressed |
| Aripiprazole | Aripiprazole | 35 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 35 | suppressed |
| Xarelto | Rivaroxaban | 35 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 32 | 32 |
| Latanoprost | Latanoprost | 31 | 11 |
| Scopolamine | Scopolamine | 29 | suppressed |
| Amantadine | Amantadine Hcl | 26 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 26 | suppressed |
| Spironolactone | Spironolactone | 26 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 25 | 13 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 24 | 18 |
| Farxiga | Dapagliflozin Propanediol | 24 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 24 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 24 | suppressed |
| Myrbetriq | Mirabegron | 24 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 23 | suppressed |
| Cephalexin | Cephalexin | 23 | 20 |
| Ertapenem | Ertapenem Sodium | 23 | suppressed |
| Nifedipine Er | Nifedipine | 23 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 22 | suppressed |
| Ibuprofen | Ibuprofen | 22 | suppressed |
| Rytary | Carbidopa/Levodopa | 22 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 21 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 21 | suppressed |
| Fenofibrate | Fenofibrate | 21 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 21 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 21 | suppressed |
| Lovastatin | Lovastatin | 21 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 20 | suppressed |
| Digoxin | Digoxin | 20 | suppressed |
| Nystatin | Nystatin | 20 | 15 |
| Nystop | Nystatin | 20 | 13 |
| Albuterol Sulfate | Albuterol Sulfate | 19 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 19 | 16 |
| Bethanechol Chloride | Bethanechol Chloride | 19 | suppressed |
| Calcitriol | Calcitriol | 19 | suppressed |
| Budesonide | Budesonide | 18 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 18 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 18 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 17 | 14 |
| Enalapril Maleate | Enalapril Maleate | 17 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 17 | suppressed |
| Chlorthalidone | Chlorthalidone | 16 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 16 | 13 |
| Glimepiride | Glimepiride | 16 | suppressed |
| Januvia | Sitagliptin Phosphate | 16 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 16 | suppressed |
| Valproic Acid | Valproic Acid | 16 | suppressed |
| Clozapine | Clozapine | 15 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 15 | suppressed |
| Methimazole | Methimazole | 15 | suppressed |
| Cefdinir | Cefdinir | 14 | 13 |
| Cefuroxime | Cefuroxime Axetil | 14 | 13 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 14 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 14 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 14 | suppressed |
| Linzess | Linaclotide | 14 | suppressed |
| Meloxicam | Meloxicam | 14 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 14 | 11 |
| Novolog Flexpen | Insulin Aspart | 14 | suppressed |
| Pentoxifylline | Pentoxifylline | 14 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 13 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 13 | suppressed |
| Levalbuterol Hcl | Levalbuterol Hcl | 13 | suppressed |
| Lokelma | Sodium Zirconium Cyclosilicate | 13 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 13 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 13 | suppressed |
| Hydrocortisone | Hydrocortisone | 12 | suppressed |
| Klayesta | Nystatin | 12 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 12 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 12 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 12 | suppressed |
| Ondansetron Odt | Ondansetron | 12 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 12 | suppressed |
| Vancomycin Hcl | Vancomycin/Water For Inj (Peg) | 12 | suppressed |
| Verapamil Er | Verapamil Hcl | 12 | suppressed |
| Acetic Acid | Acetic Acid | 11 | suppressed |
| Atenolol | Atenolol | 11 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 11 | suppressed |
| Erythromycin | Erythromycin Base | 11 | suppressed |
| Loperamide | Loperamide Hcl | 11 | suppressed |
| Phenytoin | Phenytoin | 11 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 11 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 11 | 11 |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $162.22 · 2 records | Otsuka America Pharmaceutical, Inc. | INGREZZA, REXULTI | — | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error